0001370053-20-000007.txt : 20200302 0001370053-20-000007.hdr.sgml : 20200302 20200302084954 ACCESSION NUMBER: 0001370053-20-000007 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200302 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 20674336 BUSINESS ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 8-K 1 anab-q4198xk.htm 8-K Document
false0001370053 0001370053 2020-03-02 2020-03-02
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: March 2, 2020
(Date of earliest event reported)

ANAPTYSBIO, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
001-37985
20-3828755
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
            
10421 Pacific Center Court, Suite 200
San Diego, CA 92121
(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295
(Registrant’s Telephone Number, Including Area Code)

Not Applicable
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
☐Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
☐Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ANAB
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 2.02 Results of Operations and Financial Condition.
On March 2, 2020, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months and the year ended December 31, 2019. A copy of the press release is attached as Exhibit 99.01 to this Current Report on Form 8-K.
The information in this Item 2.02, including Exhibit 99.01 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.01 shall not be incorporated by reference into any registration statement or other document filed by AnaptysBio with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
AnaptysBio, Inc.
Date: March 2, 2020
By:
/s/ Eric Loumeau
 
 
Name: Eric Loumeau
 
 
Title: Interim Chief Financial Officer and General Counsel

                   

 



 
 EX-99.1 2 q419earningsrelease.htm EXHIBIT 99.1 Exhibit


AnaptysBio Announces Fourth Quarter and Full Year 2019 Financial Results and
Provides Pipeline Updates
•
Interim Top-Line Data From Etokimab ECLIPSE Phase 2 Trial in Chronic Rhinosinusitis with Nasal Polyps Anticipated in First Half of 2020
•
Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis and Anticipate Additional Clinical Data and Regulatory Update During 2020
•
Phase 1 Trial of Company’s Third Wholly-Owned Program, ANB030, an anti-PD-1 Agonist Antibody, Anticipated in First Half of 2020 Following IND Submission in Q4 2019
•
GlaxoSmithKline (GSK) Announced BLA Submission of Dostarlimab, a PD-1 Antagonist Antibody Partnered With AnaptysBio, in Endometrial Cancer
SAN DIEGO, March 2, 2020 - AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the fourth quarter and year ended December 31, 2019 and provided pipeline updates.

“We look forward to three Phase 2 clinical trial readouts from our wholly-owned etokimab and ANB019 programs and the expansion of our pipeline with ANB030 and ANB032 during 2020,” said Hamza Suria, president and chief executive officer of AnaptysBio. “AnaptysBio is a capital-efficient antibody discovery and development engine that has been validated by the advancement of 7 internally-generated therapeutics to the clinic over the last 4 years, and we look forward to anticipated FDA approval of dostarlimab under our GSK partnership.”

Etokimab (ANB020 Anti-IL-33) Program
•
AnaptysBio is conducting a randomized, placebo-controlled Phase 2 trial in approximately 100 adult patients with chronic rhinosinusitis with nasal polyps, also referred to as the ECLIPSE trial. Patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo, each in combination with mometasone furoate nasal spray as background therapy. The Company anticipates topline data from an interim analysis of the ECLIPSE trial in the first half of 2020.
•
The Company previously announced data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index (EASI) relative placebo at week 16. AnaptysBio has discontinued development of etokimab in moderate-to-severe atopic dermatitis.
•
The Company has decided to postpone the initiation of its planned Phase 2b etokimab clinical trial in eosinophilic asthma, a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients, until results are available from the ECLIPSE trial.

ANB019 (Anti-IL-36 Receptor) Program
•
In September, AnaptysBio announced positive topline data from an interim analysis of its Phase 2 clinical trial of ANB019 monotherapy in moderate-to-severe generalized pustular psoriasis, or GPP, also known as the GALLOP trial. In this interim analysis, both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy, demonstrated rapid and sustained mJDA score improvement, with reduction of 58% at Day 8 and 63% at Day 113, and showed complete clearance of skin pustules by Day 8 and through Day 113, with CRP levels decreasing to nearly normal. Enrollment is ongoing in the GALLOP study, and the Company anticipates additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during 2020.




•
The Company is also conducting a randomized, placebo-controlled, multi-dose Phase 2 trial in 50 patients with palmoplantar pustulosis, or PPP, also known as the POPLAR trial, with topline data anticipated in the second half of 2020.
•
AnaptysBio has taken steps to enhance enrollment in the GALLOP and POPLAR trials, including expansion of clinical trial sites and countries.
ANB030 (Anti-PD-1 Agonist) Program
•
ANB030 is a wholly-owned antibody that binds PD-1 in an agonistic manner, leading to reduced T cell activity and anti-inflammatory effects in vivo. Genetic mutations in the PD-1 pathway are associated with increased susceptibility to various inflammatory conditions and we believe ANB030 has the potential to suppress inflammatory diseases by restoring insufficient PD-1-mediated negative signaling on activated T cells. The Company plans to focus future clinical development of ANB030 on certain autoimmune diseases where PD-1 checkpoint receptor function may be under-represented, submitted an Investigational New Drug Application (IND) in the fourth quarter of 2019 and plans to initiate a Phase 1 clinical trial in the first half of 2020. Preclinical data from the ANB030 was presented in June at the 2019 FOCIS Annual Meeting.
ANB032 (Anti-BTLA Modulator) Program
•
Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We anticipate filing an IND for ANB032 in the second half of 2020.
Dostarlimab (Anti-PD-1 Antagonist) Program Partnered with GSK
•
GSK has recently announced that a first BLA filing for dostarlimab, an AnaptysBio-generated PD-1 antagonist antibody under partnership with TESARO, a GSK company, occurred in the fourth quarter of 2019 for the treatment of endometrial cancer. AnaptysBio anticipates receiving a $10.0 million cash milestone payment upon acceptance of this BLA filing and a $20.0 million cash milestone upon first FDA approval of dostarlimab. Including additional cash milestones due upon future development and commercialization of dostarlimab, TSR-022, an AnaptysBio-generated TIM-3 antibody, and TSR-033, an AnaptysBio-generated LAG-3 antibody, AnaptysBio can potentially receive a total of $1.1 billion in aggregate milestone payments under this GSK partnership. In addition, AnaptysBio is due a 4% to 8% royalty from GSK, tiered upon global sales, for each of the aforementioned programs.
Board of Directors
•
In September, the Company appointed Laura J. Hamill to its board of directors. Most recently, Ms. Hamill served as Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, where she was involved in the strategic direction and long-term planning of the organization. Previously, Ms. Hamill held a number of US and international executive roles at Amgen, culminating with Senior Vice President and General Manager where she led ~$20B in U.S. commercial operations.
Fourth Quarter and Full Year Financial Results
•
Cash, cash equivalents and investments totaled $428.5 million as of December 31, 2019 compared to $500.2 million as of December 31, 2018, for a decrease of $71.7 million. The decrease relates primarily to cash used for operating activities.
•
Collaboration revenue was $3.0 million and $8.0 million for the three months and year ended December 31, 2019, which related to a milestone for initiation of a Phase 2 trial for TSR-033, the anti-LAG-3 antibody partnered with TESARO, a GlaxoSmithKline (GSK) company, compared to zero and $5.0 million for the three and year ended December 31, 2018.
•
Research and development expenses were $21.4 million and $99.3 million for the three months and year ended December 31, 2019, compared to $15.9 million and $56.2 million for the three months and year




ended December 31, 2018. The increase was due primarily to continued advancement of the Company’s etokimab and ANB019 clinical programs and additional personnel-related expenses, including share-based compensation.
•
General and administrative expenses were $3.8 million and $16.1 million for the three months and year ended December 31, 2019, compared to $3.7 million and $15.5 million for the three months and year ended December 31, 2018. The increase was due primarily to personnel-related expenses, including share-based compensation.
•
Net loss was $20.3 million and $97.3 million for the three months and year ended December 31, 2019, or a net loss per share of $0.75 and $3.60, compared to a net loss of $17.0 million and $61.7 million for the three months and year ended December 31, 2018, or a net loss per share of $0.64 and $2.50.
Financial Guidance
AnaptysBio expects its net cash burn in 2020 will be approximately $60.0 million, and that its cash, cash equivalents and investments will fund its current operating plan at least into 2023.

About AnaptysBio
AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody etokimab, previously referred to as ANB020, for the treatment of chronic rhinosinusitis with nasal polyps, or CRSwNP, and eosinophilic asthma; its anti-IL-36R antibody ANB019 for the treatment of rare inflammatory diseases, including generalized pustular psoriasis, or GPP, and palmoplantar pustulosis, or PPP; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated, and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO, a GSK company, including an anti-PD-1 antagonist antibody (dostarlimab (TSR-042)), an anti-TIM-3 antagonist antibody (TSR-022) and an anti-LAG-3 antagonist antibody (TSR-033), and an inflammation partnership with Celgene, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our clinical trials, including etokimab’s Phase 2 clinical trial in adult patients with CRSwNP and ANB019’s Phase 2 clinical trials in GPP and PPP, the timing of and our ability to launch a Phase 2b clinical trial of etokimab in eosinophilic asthma patients, the timing of a regulatory strategy update for GPP, the timing of initiation of a Phase 1 clinical trial for ANB030, the timing of an IND filing for ANB032, the milestones and royalty payments to be received under the GSK partnership, and our projected 2020 cash burn and cash runway. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the




company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact:
Eric Loumeau
AnaptysBio, Inc.
858.732.0179
eloumeau@anaptysbio.com




ANAPTYSBIO, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value)
 
December 31, 2019
 
December 31, 2018
 
 
 
 
ASSETS
Current assets:
 
 
 
Cash and cash equivalents
$
171,017

 
$
113,596

Australian tax incentive receivable
—

 
174

Short-term investments
203,210

 
313,486

Prepaid expenses and other current assets
3,506

 
6,960

Total current assets
377,733

 
434,216

Property and equipment, net
1,618

 
1,445

Long-term investments
54,305

 
73,128

Other long-term assets
1,481

 
148

Restricted cash
60

 
60

Total assets
$
435,197

 
$
508,997

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
 
 
 
Accounts payable
$
16,237

 
$
5,443

Accrued expenses
11,052

 
8,761

Notes payable, current portion
1,375

 
7,574

Other current liabilities
871

 
58

Total current liabilities
29,535

 
21,836

Other long-term liabilities
654

 
796

Stockholders’ equity:
 
 
 
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2019 and December 31, 2018, respectively
—

 
—

Common stock, $0.001 par value, 500,000 shares authorized, 27,255 shares and 26,922 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively
27

 
27

Additional paid in capital
648,669

 
633,251

Accumulated other comprehensive income (loss)
338

 
(223
)
Accumulated deficit
(244,026
)
 
(146,690
)
Total stockholders’ equity
405,008

 
486,365

Total liabilities, preferred stock and stockholders’ equity
$
435,197

 
$
508,997







ANAPTYSBIO, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
 
Three Months Ended
December 31,
 
Year Ended
December 31,
 
2019
 
2018
 
2019
 
2018
Collaboration revenue
$
3,000

 
$
—

 
$
8,000

 
$
5,000

Operating expenses:
 
 
 
 
 
 
 
Research and development
21,426

 
15,920

 
99,338

 
56,196

General and administrative
3,832

 
3,743

 
16,094

 
15,526

Total operating expenses
25,258

 
19,663

 
115,432

 
71,722

Loss from operations
(22,258
)
 
(19,663
)
 
(107,432
)
 
(66,722
)
Other income (expense), net:
 
 
 
 
 
 
 
Interest expense
(200
)
 
(365
)
 
(1,041
)
 
(1,652
)
Interest income
2,282

 
2,834

 
10,984

 
6,685

Other (expense) income, net
(109
)
 
8

 
1

 
(159
)
Total other income (expense), net
1,973

 
2,477

 
9,944

 
4,874

Loss before income taxes
(20,285
)
 
(17,186
)
 
(97,488
)
 
(61,848
)
Provision for income taxes
22

 
192

 
152

 
192

Net loss
(20,263
)
 
(16,994
)
 
(97,336
)
 
(61,656
)
Other comprehensive income (loss):
 
 
 
 
 
 
 
Unrealized income (loss) on available for sale securities, net of tax of ($36), $55, $153, and $55, respectively
(142
)
 
318

 
561

 
203

Comprehensive loss
$
(20,405
)
 
$
(16,676
)
 
$
(96,775
)
 
$
(61,453
)
Net loss per common share:
 
 
 
 
 
 
 
      Basic and diluted
$
(0.75
)
 
$
(0.64
)
 
$
(3.60
)
 
$
(2.50
)
Weighted-average number of shares outstanding:
 
 
 
 
 
 
 
      Basic and diluted
27,154

 
26,788

 
27,059

 
24,673




 EX-101.SCH 3 anab-20200303.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 anab-20200303_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 anab-20200303_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 anab-20200303_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover page. Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 anab-20200303_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover Page
Mar. 02, 2020
Cover page.  
Document Type 8-K
Document Period End Date Mar. 02, 2020
Entity Registrant Name ANAPTYSBIO, INC
Entity Incorporation, State or Country Code DE
Entity File Number 001-37985
Entity Tax Identification Number 20-3828755
Entity Address, Address Line One 10421 Pacific Center Court
Entity Address, Address Line Two Suite 200
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 362-6295
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ANAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001370053
Amendment Flag false
XML 9 anab-q4198xk_htm.xml IDEA: XBRL DOCUMENT 0001370053 2020-03-02 2020-03-02 false 0001370053 8-K 2020-03-02 ANAPTYSBIO, INC DE 001-37985 20-3828755 10421 Pacific Center Court Suite 200 San Diego CA 92121 858 362-6295 false false false false Common Stock, par value $0.001 per share ANAB NASDAQ false ZIP 10 0001370053-20-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001370053-20-000007-xbrl.zip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

XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.anaptysbio.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports anab-q4198xk.htm anab-20200303.xsd anab-20200303_cal.xml anab-20200303_def.xml anab-20200303_lab.xml anab-20200303_pre.xml q419earningsrelease.htm http://xbrl.sec.gov/dei/2019-01-31 true true EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anab-q4198xk.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "anab-20200303_cal.xml" ] }, "definitionLink": { "local": [ "anab-20200303_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "anab-q4198xk.htm" ] }, "labelLink": { "local": [ "anab-20200303_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "anab-20200303_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "anab-20200303.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "anab", "nsuri": "http://www.anaptysbio.com/20200303", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "anab-q4198xk.htm", "contextRef": "D2020Q1Mar2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.anaptysbio.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "anab-q4198xk.htm", "contextRef": "D2020Q1Mar2", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.anaptysbio.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 16 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }